AI assistant
Sending…
SUTRO BIOPHARMA, INC. — Director's Dealing 2021
Feb 1, 2021
34319_dirs_2021-02-01_2597a78a-f7ee-4f7c-8495-3c778b7e871a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-01-29
Reporting Person: Shabbir Anik (Chief Technical Ops. Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-01-29 | Common Stock | M | 4500 | $0.00 | Acquired | 15765 | Direct |
| 2021-01-29 | Common Stock | F | 1845 | $22.15 | Disposed | 13920 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-01-29 | Restricted Stock Unit (RSU) | $ | M | 4500 | Disposed | 2024-01-29 | Common Stock (4500) | Direct |
Footnotes
F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F2: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3: The RSUs vest as to 1/4th of the total shares annually beginning on January 29, 2021, subject to continued service through each vesting date.
More from SUTRO BIOPHARMA, INC.
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Annual Report
2026
Apr 22
Capital/Financing Update
2026
Apr 1
Capital/Financing Update
2026
Mar 23
Annual Report
2026
Mar 23
Regulatory Filings
2026
Mar 23
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3